Elpiscience (Suzhou) Biopharma, Ltd.
šØš³China
- Country
- šØš³China
- Ownership
- Private, Subsidiary
- Established
- 2018-03-20
- Employees
- -
- Market Cap
- -
- Website
- https://cn.elpiscience.com
Robust Pipeline of 200+ Therapies Targets Colorectal Cancer Treatment Landscape
ā¢ DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.
ā¢ Key drug candidates include XL092 (Exelixis), Adagrasib (Mirati Therapeutics), Olaparib (Merck/AstraZeneca), and novel approaches like LYL845, an autologous tumor-infiltrating lymphocyte therapy from Lyell Immunopharma.
ā¢ The metastatic colorectal cancer segment shows particular promise with 150+ companies advancing 180+ pipeline therapies, including innovative treatments targeting specific mutations and immune pathways.
Ā© Copyright 2025. All Rights Reserved by MedPath